The provision of information, data, analysis and other evidence in the dossier shall follow international standards of evidence-based medicine. The health technology developer shall consult, if available, the methodological guidance adopted by the Member State Coordination Group on Health Technology Assessment (‘Coordination Group’) under Article 3(7), point (d), of Regulation (EU) 2021/2282 where applicable and describe and justify any deviations from that guidance. The information requested in the dossier template shall be provided in a clear format, preferably in tabular format when possible.
Unnecessary lines shall be deleted. If needed, lines may be added.
Version | Document | Legal reference | Submission date | Commission’s check date
V0.1 | Initial dossier | Article 10(2) of Regulation (EU) 2021/2282 | |
V0.2 | (Updated dossier following Commission’s second request) | Article 10(5) of Regulation (EU) 2021/2282 | |
V0.3 | (Updated dossier following assessors’ request for further specifications, clarifications or additional information) | Article 11(2) of Regulation (EU) 2021/2282 | | N/A
V0.4 | (Updated dossier following re-initiation of a JCA) | Article 10(8) of Regulation (EU) 2021/2282 | | N/A
V0.5 | (Dossier with the HTD’s indications and justification of confidential information) | Article 11(5) of Regulation (EU) 2021/2282 | | N/A
V1.0 | Dossier for publication (without confidential information) | Article 21 of Implementing Regulation (EU) 2025/2086 | N/A |
V1.0.1 | (Updated dossier where the joint clinical assessment report specifies the need for an update and additional evidence for further assessment becomes available) | Article 19(1) of Implementing Regulation (EU) 2025/2086 | | N/A
V1.0.2 | (Updated dossier provided on the initiative of the HTD where additional evidence for further assessment becomes available) | Article 19(2) of Implementing Regulation (EU) 2025/2086 | | N/A
V1.0.3 | (Updated dossier following the initiation of an update of a JCA – update of the assessment scope not needed) | Article 19(5) of Implementing Regulation (EU) 2025/2086 | |
V1.0.4 | (Updated dossier following the initiation of an update of a JCA – update of the assessment scope needed) | Article 19(6) of Implementing Regulation (EU) 2025/2086 | |
V1.0.5 | (Updated dossier following the initiation of an update of a JCA with the HTD’s indications and justification of confidential information) | Article 11(5) of Regulation (EU) 2021/2282 | | N/A
V2.0 | (Dossier for publication following the finalisation of an update of a JCA (without confidential information)) | Article 21 of Implementing Regulation (EU) 2025/2086 | N/A |
The following list presents suggestions for abbreviations. It may be adapted to the dossier. Supplementary lines may be added, if needed.
Abbreviation | Meaning
CER | Clinical evaluation report as referred to in Article 61(12) of Regulation (EU) 2017/745 and part A of Annex XIV to Regulation (EU) 2017/745
CIP | Clinical investigation plan as referred to in Section 3 Chapter II of Annex XV to Regulation (EU) 2017/745
CIR | Clinical investigation report as referred to in Section 7 Chapter III of Annex XV to Regulation (EU) 2017/745
EEA | European Economic Area
HTA | Health Technology Assessment
HTD | Health Technology Developer
JCA | Joint Clinical Assessment
JSC | Joint Scientific Consultation
MD | Medical Device
PMCF | Post-Market Clinical Follow-up
PICO | A set of parameters for the joint clinical assessment in terms of: Patient Population – Intervention(s) – Comparator(s) – Health Outcomes
Overview
1.1. Information about the medical device under assessment (‘the medical device’) and the HTD
This section shall provide:
the trade name of the medical device;
the corporate name and permanent address of the HTD submitting the dossier for the JCA. In case the manufacturer to which the certificate of conformity for the medical device was issued is different from the HTD submitting the dossier, the corporate name and address of both the manufacturer and the HTD shall be specified.
1.2. Previous assessments under Regulation (EU) 2021/2282 (point e of Annex II.1 to Regulation (EU) 2021/2282)
This section shall indicate whether the medical device has been subject to a previous assessment under Regulation (EU) 2021/2282, either for the same medical indication or for another medical indication. If the answer is positive, the section shall provide the medical indication, the date and the reference of the previous JCA report.
1.3. Executive summary (points j to m of Annex II.1 to Regulation (EU) 2021/2282)
This section shall provide a concise executive summary of the dossier focusing on the assessment scope as set out pursuant to Article 8(6) of Regulation (EU) 2021/2282 and shared with the HTD in the Commission’s first request referred to in Article 10(1) of Regulation (EU) 2021/2282 (‘the assessment scope’). The executive summary shall include:
the identification of any PICO(s) for which data was not submitted;
a summary of the data analysed (e.g. effect measures with statistical precision for each outcome) with regard to the assessment scope, indicating whether the results were based on direct or indirect evidence. The data shall be provided for each PICO separately;
the degree of certainty with regard to the PICO(s).
Background
2.1. Characterisation of the medical condition to be treated, prevented or diagnosed (point h of Annex II.1 to Regulation (EU) 2021/2282)
2.1.1. Overview of the medical condition
This section shall:
describe the medical condition which the medical device intends to treat, monitor, alleviate, compensate, prevent or diagnose, including criteria for its diagnosis, if available, using a standardised code such as the International Statistical Classification of Diseases and Related Health Problems (‘ICD’) code or the Diagnostic and Statistical Manual of Mental Disorders (‘DSM’) code and the version of the code;
where relevant, describe the main stages and/or subtypes of the medical condition;
include any prognostic factors that may affect the course of the disease or medical condition and the prognosis of the medical condition without the new treatment;
present an estimate of the most recent prevalence and/or incidence for the medical condition in the EEA States and, where relevant, describe any profound differences between these EEA States;
describe the symptoms and burden of the medical condition for patients, including aspects such as pain, disability, psychosocial issues, and other determinants of morbidity and quality of life from a patient’s perspective;
for medical conditions that result in disability and/or a need for a family caregiver, and for treatments that result in major organisational changes to the healthcare system (e.g., due to manufacturing constraints) or major associated procedures: briefly describe the organisational and societal impact of the medical condition and its treatment, giving some context for interpretation of outcomes.
References for the statements shall be provided. Full texts of references shall be provided in Appendix D.1.
2.1.2. Characterisation of the target patient population
In case the target population is more specific than the overall medical condition, this section shall:
name and describe the default target patient population(s) for the indication(s), in line with the intended purpose specified in the product certificate and summary of safety and clinical performance of the device (where relevant);
describe and justify the proposed position of the target patient population(s) in the patient pathway of care;
where relevant, take into account sex, age and other specific characteristics;
describe any patient sub-populations, including the criteria for their identification, if specifically defined in the assessment scope, and further patient sub-populations, if appropriate;
describe the natural progression of the medical condition (by patient sub-population, if appropriate).
References for the statements shall be provided. Full texts of references shall be provided in Appendix D.1.
2.1.3. Clinical management of the medical condition
This section shall:
describe the care pathway for the medical condition, which the medical device intends to treat, monitor, alleviate, compensate, prevent or diagnose where relevant, for different stages and/or subtypes of the disease or medical condition or patient sub-populations, with diagrams of the care pathway(s) that include comparator(s);
where care pathways vary substantially between the EEA States, briefly describe these variations in care;
include a list of relevant clinical guidelines at the European level, e.g., by European medical associations or societies, if available.
References for the statements shall be provided. Full texts of references shall be provided in Appendix D.1.
2.2. Characterisation of the medical device (point i of Annex II.1 to Regulation (EU) 2021/2282)
2.2.1. Characteristics of the medical device
This section shall describe the characteristics of the medical device and in particular, report the following information:
model(s) of the medical device including description of the different references / reference number(s) / software version;
Basic UDI-DI(s) referred to in the current certificate of conformity;
risk class of the medical device;
European Nomenclature on Medical Devices (EMDN) [European Medical Device Nomenclature (EMDN) - EUDAMED.] description (most granular level, as relevant);
intended purpose;
brief description of the medical device including its constituents;
mode(s) of action;
frequency and duration of use;
claimed device lifetime;
when previous versions of the medical device are available, description of the main changes made to these different versions;
if applicable, specific description for the connected technology;
for medical devices with an embedded decision-making system based on machine learning and artificial intelligence processes, description of the functions built-in or evolving using these technologies.
References for the statements shall be provided. Full texts of references shall be provided in Appendix D.1.
2.2.2. Summary of the main requirements for use
This section shall:
describe procedures including surgical procedures, and services associated with the use of the medical device;
describe organisational aspects associated with the use of the medical device, in particular any specifically qualified personnel, training of users, specific equipment and special facilities required to use the medical device, including any specific tests or investigations required. Where such equipment has been fully described in Section 2.2.1, the current section shall refer to the above description and state that there are no additional requirements;
describe any additional supplies (except generic supplies) required to use the medical device, where applicable.
These characteristics shall be specified by sub-population, if appropriate.
References for the statements shall be provided. Full texts of references shall be provided in Appendix D.1.
2.2.3. Regulatory status of the medical device
This section shall:
provide the regulatory status of the medical device in the indication considered for this JCA in Australia, Canada, China, Japan, United Kingdom, United States of America and other countries if relevant;
indicate the date on which the medical device was placed on the EU market, where applicable;
detail ongoing or planned early access/compassionate use programs in the EEA States;
specify if the medical device has been certified under Regulation (EU) 2017/745 for other indications than the indication considered for this JCA.
References for the statements shall be provided. Full texts of references shall be provided in Appendix D.1.
2.3. JSC related to the JCA (point g of Annex II.1 to Regulation (EU) 2021/2282)
Where the medical device has been subject to a JSC under of Regulation (EU) 2021/2282, this section shall explain any deviation from the recommended proposition for evidence generation. The recommendations shall be documented in Appendix D.8.
Assessment scope (point j of Annex II.1 to Regulation (EU) 2021/2282)
This section shall:
reproduce the assessment scope in the format shared with the HTD in the Commission’s first request referred to in Article 10(1) of Regulation (EU) 2021/2282;
clearly identify any PICO(s), for which data is not submitted and explain the reasons for this omission.
Description of methods used in the development of the content of the dossier (point k of Annex II.1 to Regulation (EU) 2021/2282)
This section shall describe the methods used in the development of the content of the dossier. The HTD shall consult, if available, the methodological guidance adopted by the Coordination Group pursuant to Article 3(7), point (d), of Regulation (EU) 2021/2282.
4.1. Criteria for selecting studies for JCA
This section shall specify the inclusion and exclusion criteria for studies to be considered for this JCA based on the assessment scope. The HTD shall consult, if available, the methodological guidance adopted by the Coordination Group pursuant to Article 3(7), point (d), of Regulation (EU) 2021/2282. The specification for inclusion and exclusion criteria shall be provided for each PICO, as appropriate.
4.2. Information retrieval and selection of relevant studies
4.2.1. Information retrieval
The HTD shall explain the conduct of the information retrieval process with the objective of identifying the evidence to be used for the preparation of the dossier, systematically considering the following sources of information:
clinical efficacy and safety studies and where relevant, other applicable studies conducted or sponsored by the HTD or by third parties, including ongoing studies, in order to include all up-to-date published and unpublished information (data, analyses and any other evidence) from studies on the medical device for which the HTD was a sponsor and corresponding information about studies by third parties, if available;
bibliographic databases, including at least the National Library of Medicine's bibliographic database (MEDLINE) and the Cochrane Central Register of Controlled Trials database;
study registries and study results registries (clinical trial databases);
HTA reports on the medical device subject to the JCA from the EEA States and from Australia, Canada, the United Kingdom and the United States of America;
clinical evaluation report (CER);
medical device and patient registries.
This section shall:
provide a list of the sources that were systematically searched for studies that are relevant for the JCA according to the assessment scope and indicate the date of each search, with a cut-off date for the searches of a maximum of 3 months before the submission of the dossier;
report whether and when new data with relevance for the assessment scope might become available.
All search strategies shall be fully documented in Appendix D.2.
4.2.2. Selection of relevant studies
This section shall document the approach for the selection of relevant studies from the results of the information retrieval according to inclusion and exclusion criteria defined in Section 4.1. That specification shall be provided for each PICO, as appropriate. The HTD shall consult the selection process suggested in the methodological guidance adopted by the Coordination Group pursuant to Article 3(7), point (d), of Regulation (EU) 2021/2282.
4.3. Methods for data analysis and synthesis
This section shall describe the methods used for data analysis and synthesis following international standards of evidence-based medicine. The HTD shall consult, if available, the methodological guidance adopted by the Coordination Group pursuant to Article 3(7), point (d), of Regulation (EU) 2021/2282 and describe and justify any deviations from that guidance.
The underlying documentation for any analysis, i.e. study protocols and statistical analysis plans (including for evidence syntheses) and details on all software used, as well as the respective program code and relevant output shall be provided in the relevant parts of Appendix D.
This section shall cover the following methodological aspects in the following respective sub-sections, where relevant:
4.3.1. Description of the design and methodology of the included original clinical studies
4.3.2. Direct comparisons by pairwise meta-analyses
The protocol for evidence syntheses, including the relevant statistical analysis plan, shall be provided in Appendix D.5.
4.3.3. Indirect comparisons
The protocol for evidence syntheses, including the relevant statistical analysis plan, shall be provided in Appendix D.5.
4.3.4. Sensitivity analyses
This section shall describe and justify the methods of all performed sensitivity analyses. It shall describe the purpose or which methodological parameter the sensitivity analysis addresses, as well as underlying assumptions.
4.3.5. Subgroup analyses and other effect modifiers
4.3.6. Specification of further methods as required
This section shall describe any other methods used in deriving results used in the dossier.
Results (point l of Annex II.1 to Regulation (EU) 2021/2282)
The results presented in the dossier shall follow international standards of evidence-based medicine. The HTD shall consult, if available, the methodological guidance adopted by the Coordination Group pursuant to Article 3(7), point (d), of Regulation (EU) 2021/2282 and describe and justify any deviations from that guidance.
The presentation of results shall use text, figures and tables as appropriate.
5.1. Results from the information retrieval process
Results from the different steps of the information retrieval process shall be presented transparently. For each study, the following information shall be indicated: the study reference ID, the study status, the study duration with data cut-off if applicable, and study arms. For each of the information retrieval steps, the studies not considered in the dossier shall be identified and listed. For each of them, the reason for exclusion shall be specified.
The presentation of the results shall include in the following respective sub-sections:
5.1.1. List of studies conducted or sponsored by the HTD or by third parties
This section shall report information on all the studies, including ongoing studies, conducted or sponsored by the HTD and third parties, referred to in point d of Annex II.1 to Regulation (EU) 2021/2282, including all studies providing clinical safety and clinical performance data from the CER. The listing shall be restricted to studies involving patients in the medical indication for which the dossier is prepared. The section shall also report whether and when new data with relevance for the assessment scope might become available during or after the assessment period.
5.1.2. Studies identified in searches of bibliographic databases
This section shall present results from searches for studies on the medical device and its comparator(s) where relevant (e.g. for indirect meta-analyses) in bibliographic databases.
5.1.3. Studies in study registries and study results registries (clinical trial databases)
In accordance with point f of Annex II.1 to Regulation (EU) 2021/2282, this section shall present results from searches for studies for the medical devices and its comparator(s) where relevant in study registries/study results registries.
5.1.4. HTA reports
In accordance with point e of Annex II.1 to Regulation (EU) 2021/2282, this section shall list HTA reports available on the medical device subject to the JCA from the EEA States and from Australia, Canada, the United Kingdom and the United States of America. The HTA reports shall be provided in Appendix D.6. Any additional relevant evidence identified in those HTA reports which were not identified in other sources shall be listed.
5.1.5. Studies from the CER
This section shall list all clinical performance and safety studies and where relevant, other applicable studies that were included in the CER. If the main studies do not address any of the PICO(s), they shall be presented in Appendix C and be provided in Appendix D.10.
5.1.6. Studies from medical device and patient registries
This section shall present results from searches for studies for the medical device and its comparator(s), where relevant, in medical device and patient registries.
5.1.7. List of included studies overall and by PICO
This section shall define the list of studies included in the dossier informing each PICO. If no evidence is available for a specific PICO question in the assessment scope, this shall be clearly reported in the dossier (‘No evidence provided by the HTD’) and duly justified.
5.2. Characteristics of included studies
In accordance with point m of Annex II.1 to Regulation (EU) 2021/2282, this section shall provide an overview in tabular format of the study design and the study population for all studies included in the dossier to address any of the PICO(s). Information shall specifically be provided on:
the study type and design;
the study date and duration;
enrolled study population including key eligibility criteria and locations;
characteristics of the intervention and comparator(s);
study outcomes;
if applicable, data cut-off;
sample size;
analysis methods.
The study interventions shall be characterised and information on the course of the study (i.e., planned and actual follow-up times per outcome) shall be provided.
The studies included in the dossier shall be described briefly. A detailed description of the study methodology shall be provided in Appendix A.
5.3. Data analysis
In accordance with Articles 9(2) and (3) of Regulation (EU) 2021/2282, this section shall present the data analysed to address each research question of the assessment scope. The data shall be presented by PICO. The presentation shall follow international standards of evidence-based medicine. The HTD shall consult, if available, the methodological guidance adopted by the Coordination Group under Article 3(7), point (d), of Regulation (EU) 2021/2282 and describe and justify any deviations from that guidance.
This section shall also provide all information that is required to assess the degree of certainty with regard to the PICO(s), taking into account the strengths and limitations of the available evidence, including, but not limited to, the risk of biases.
Details shall be provided in the relevant Appendixes.
List of references